A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Back to Search
Print
Bookmark Trial

NCT00312351

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Charlotte Eye, Ear, Nose and Throat Associates, P.A.
Charlotte, North Carolina, 28210, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects of either gender, aged 50 years or greater.

- Subfoveal choroidal neovascularization (CNV) due to AMD.

- Best corrected visual acuity in the study eye between 20/40 and 20/320.

- Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Macular DegenerationA Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00312351
  1. Charlotte, North Carolina
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Macular DegenerationIntravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
NCT00088192
  1. Los Angeles, California
  2. Bridgeport, Connecticut
  3. Hamden, Connecticut
  4. Fort Myers, Florida
  5. New Orleans, Louisiana
  6. Hagerstown, Maryland
  7. Boston, Massachusetts
  8. Boston, Massachusetts
  9. Royal Oak, Michigan
  10. Kansas City, Missouri
  11. Concord, New Hampshire
  12. Belleville, New Jersey
  13. Teaneck, New Jersey
  14. Great Neck, New York
  15. Lakewood, Ohio
  16. Oklahoma City, Oklahoma
  17. Portland, Oregon
  18. Columbia, South Carolina
  19. McAllen, Texas
  20. Burlington, Vermont
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Macular DegenerationLong-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
NCT00845273
ALL GENDERS
0+
years
MULTIPLE SITES
Macular DegenerationClinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
NCT00239928
  1. Nagoya, Aichi
  2. Urayasu, Chiba
  3. Fukuoka-shi, Fukuoka-ken
  4. Maebashi, Gunma
  5. Sapporo, Hokkaido
  6. Moriguchi, Osaka
  7. Suita, Osaka
  8. Otsu, Shiga
  9. Chiyoda-ku, Tokyo
  10. Shinjuku-ku, Tokyo
  11. Fukushima,
  12. Kyoto,
ALL GENDERS
51 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Official Title  ICMJE An Exploratory Randomized, Double-Masked, Multi-Center Comparative Trial, in Parallel Groups, to Explore the Safety and Efficacy of Three Different Doses of Intravitreous Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 102 Weeks, in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (AMD)
Brief Summary The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Macular Degeneration
Intervention  ICMJE Drug: Pegaptanib sodium
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: April 7, 2006)		262
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE November 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects of either gender, aged 50 years or greater.
  • Subfoveal choroidal neovascularization (CNV) due to AMD.
  • Best corrected visual acuity in the study eye between 20/40 and 20/320.
  • Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more.

Exclusion Criteria:

  • Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 50 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00312351
Other Study ID Numbers  ICMJE EOP1014
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Eyetech Pharmaceuticals
Collaborators  ICMJE Pfizer
Investigators  ICMJE Not Provided
PRS Account Eyetech Pharmaceuticals
Verification Date January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP